Resistance to gefitinib in PTEN-Null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling
Qing Bai She, David Solit, Andrea Basso, Mark M. Moasser
Research output: Contribution to journal › Article › peer-review
274Scopus
citations
Fingerprint
Dive into the research topics of 'Resistance to gefitinib in PTEN-Null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling'. Together they form a unique fingerprint.